Global pipeline of products for neglected diseases

- **220 vaccines**
- **189 drugs**
- **~153 diagnostics**
- **23 vector control products**

585 products under development

**Technology Type**

**Health Areas/Diseases**

- **141 tuberculosis**
- **135 malaria**
- **108 HIV/AIDS**
- **200 other**

---

**Ongoing need**

Lack of essential health technologies

- No HIV/AIDS vaccine
- TB treatment lasts 6–30 months, TB vaccine is 100 years old
- No suitable treatments for leishmaniasis, mycetoma, and river blindness
- New disease threats continue to emerge

1 billion people affected by neglected diseases globally

218 million women have unmet need for modern family planning

6 million annual deaths worldwide from neglected diseases

---

GHTC

Global Health Technologies Coalition
Global Spending on All Health R&D

- $286 billion

Global Spending on Neglected Disease R&D

- $3.9 billion

Only 1-2% of global spending on health R&D targets neglected diseases.

Funding for neglected disease R&D

- 67% public
- 20% philanthropic
- 13% private

The return on investment of global health R&D

- Lives saved
  - Antiretroviral therapies have prevented 12.1 million AIDS-related deaths since 2010
  - A new child-friendly malaria medicine has saved 860,000 lives since its introduction in 2009
  - The world is on the verge of eradicating polio due to the development and delivery of polio vaccines

- Economic growth
  - $0.89 of every dollar the US government invests in global health R&D goes to US-based researchers and €0.80 of every euro of EU investment is spent within the EU
  - Anti-malaria efforts are projected to provide $208.6 billion in net global economic gains by 2035
  - US government investment in global health R&D from 2007–2015 generated an estimated 200,000 new US jobs and $33 billion in economic growth

- Cost savings
  - $26 million invested in polio vaccine R&D resulted in treatment cost savings of $180 billion since 1950s
  - Every $1 invested in HIV/AIDS vaccine R&D is expected to return between $2-67 in cost savings
  - It cost $50 million to develop a low-cost meningitis A vaccine, which is estimated to have saved nearly $9 billion in treatment and other costs between 2010 and 2020

- Health security
  - Without a vaccine or other tools to combat the 2014 Ebola outbreak, it claimed 11,000+ lives and cost the US $3 billion and EU €1.2 billion to respond. Thanks to R&D efforts, we now have a vaccine.
  - Beyond saving countless lives, every $1 invested in the ACT Accelerator to develop and equitably deliver COVID-19 tools is projected to return up to $166 in economic benefit
  - By 2050, antimicrobial resistance could lead to 10 million deaths annually and cost the global economy $100 trillion
Critical US role in global health R&D

51% of new global health products approved since 2000 were supported by the US government.

40% of late-stage products in the global health pipeline were supported by the US government.

<.01% of US GDP is spent annually on global health R&D

Top public funders of neglected disease R&D

(Investment as a percent of GDP)

While the US leads the world in funding for neglected disease R&D, these investments still account for less than .01% of US GDP.

GHTC
global health technologies coalition
Infographic Data Sources

Global pipeline for neglected diseases

Funding for neglected disease R&D


Return on investment in global health R&D


Every $1 invested in the ACT Accelerator: Adhanom Ghebreysus, Tedros. “WHO Director-General’s opening remarks at the High-Level Finance Ministers’ Meeting for the ACT Accelerator.” 29 Jan 2021.


Ongoing need


Critical US role in global health R&D

Top public funders of neglected disease R&D